Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRα) and is indicated for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to...

Full description

Bibliographic Details
Main Authors: Andrew Hendershot, Mark Slabaugh, Kamran M. Riaz, Kathleen N. Moore, David M. O'Malley, Ursula Matulonis, Gottfried E. Konecny
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Gynecologic Oncology Reports
Subjects:
Ovarian cancer
Antibody-drug conjugates
Folate receptor alpha
Mirvetuximab soravtansine
Eye care
Ocular adverse events
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578923000243

Internet

http://www.sciencedirect.com/science/article/pii/S2352578923000243

Similar Items